Cargando…
Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance
Antibiotic-induced perturbation of the human gut flora is expected to play an important role in mediating the relationship between antibiotic use and the population prevalence of antibiotic resistance in bacteria, but little is known about how antibiotics affect within-host resistance dynamics. Here...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205461/ https://www.ncbi.nlm.nih.gov/pubmed/32379042 http://dx.doi.org/10.7554/eLife.49206 |
_version_ | 1783530246869352448 |
---|---|
author | Niehus, Rene van Kleef, Esther Mo, Yin Turlej-Rogacka, Agata Lammens, Christine Carmeli, Yehuda Goossens, Herman Tacconelli, Evelina Carevic, Biljana Preotescu, Liliana Malhotra-Kumar, Surbhi Cooper, Ben S |
author_facet | Niehus, Rene van Kleef, Esther Mo, Yin Turlej-Rogacka, Agata Lammens, Christine Carmeli, Yehuda Goossens, Herman Tacconelli, Evelina Carevic, Biljana Preotescu, Liliana Malhotra-Kumar, Surbhi Cooper, Ben S |
author_sort | Niehus, Rene |
collection | PubMed |
description | Antibiotic-induced perturbation of the human gut flora is expected to play an important role in mediating the relationship between antibiotic use and the population prevalence of antibiotic resistance in bacteria, but little is known about how antibiotics affect within-host resistance dynamics. Here we develop a data-driven model of the within-host dynamics of extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae. We use bla(CTX-M) (the most widespread ESBL gene family) and 16S rRNA (a proxy for bacterial load) abundance data from 833 rectal swabs from 133 ESBL-positive patients followed up in a prospective cohort study in three European hospitals. We find that cefuroxime and ceftriaxone are associated with increased bla(CTX-M) abundance during treatment (21% and 10% daily increase, respectively), while treatment with meropenem, piperacillin-tazobactam, and oral ciprofloxacin is associated with decreased bla(CTX-M) (8% daily decrease for all). The model predicts that typical antibiotic exposures can have substantial long-term effects on bla(CTX-M) carriage duration. |
format | Online Article Text |
id | pubmed-7205461 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | eLife Sciences Publications, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-72054612020-05-08 Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance Niehus, Rene van Kleef, Esther Mo, Yin Turlej-Rogacka, Agata Lammens, Christine Carmeli, Yehuda Goossens, Herman Tacconelli, Evelina Carevic, Biljana Preotescu, Liliana Malhotra-Kumar, Surbhi Cooper, Ben S eLife Epidemiology and Global Health Antibiotic-induced perturbation of the human gut flora is expected to play an important role in mediating the relationship between antibiotic use and the population prevalence of antibiotic resistance in bacteria, but little is known about how antibiotics affect within-host resistance dynamics. Here we develop a data-driven model of the within-host dynamics of extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae. We use bla(CTX-M) (the most widespread ESBL gene family) and 16S rRNA (a proxy for bacterial load) abundance data from 833 rectal swabs from 133 ESBL-positive patients followed up in a prospective cohort study in three European hospitals. We find that cefuroxime and ceftriaxone are associated with increased bla(CTX-M) abundance during treatment (21% and 10% daily increase, respectively), while treatment with meropenem, piperacillin-tazobactam, and oral ciprofloxacin is associated with decreased bla(CTX-M) (8% daily decrease for all). The model predicts that typical antibiotic exposures can have substantial long-term effects on bla(CTX-M) carriage duration. eLife Sciences Publications, Ltd 2020-05-07 /pmc/articles/PMC7205461/ /pubmed/32379042 http://dx.doi.org/10.7554/eLife.49206 Text en © 2020, Niehus et al http://creativecommons.org/licenses/by/4.0/ http://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Epidemiology and Global Health Niehus, Rene van Kleef, Esther Mo, Yin Turlej-Rogacka, Agata Lammens, Christine Carmeli, Yehuda Goossens, Herman Tacconelli, Evelina Carevic, Biljana Preotescu, Liliana Malhotra-Kumar, Surbhi Cooper, Ben S Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance |
title | Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance |
title_full | Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance |
title_fullStr | Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance |
title_full_unstemmed | Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance |
title_short | Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance |
title_sort | quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance |
topic | Epidemiology and Global Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205461/ https://www.ncbi.nlm.nih.gov/pubmed/32379042 http://dx.doi.org/10.7554/eLife.49206 |
work_keys_str_mv | AT niehusrene quantifyingantibioticimpactonwithinpatientdynamicsofextendedspectrumbetalactamaseresistance AT vankleefesther quantifyingantibioticimpactonwithinpatientdynamicsofextendedspectrumbetalactamaseresistance AT moyin quantifyingantibioticimpactonwithinpatientdynamicsofextendedspectrumbetalactamaseresistance AT turlejrogackaagata quantifyingantibioticimpactonwithinpatientdynamicsofextendedspectrumbetalactamaseresistance AT lammenschristine quantifyingantibioticimpactonwithinpatientdynamicsofextendedspectrumbetalactamaseresistance AT carmeliyehuda quantifyingantibioticimpactonwithinpatientdynamicsofextendedspectrumbetalactamaseresistance AT goossensherman quantifyingantibioticimpactonwithinpatientdynamicsofextendedspectrumbetalactamaseresistance AT tacconellievelina quantifyingantibioticimpactonwithinpatientdynamicsofextendedspectrumbetalactamaseresistance AT carevicbiljana quantifyingantibioticimpactonwithinpatientdynamicsofextendedspectrumbetalactamaseresistance AT preotesculiliana quantifyingantibioticimpactonwithinpatientdynamicsofextendedspectrumbetalactamaseresistance AT malhotrakumarsurbhi quantifyingantibioticimpactonwithinpatientdynamicsofextendedspectrumbetalactamaseresistance AT cooperbens quantifyingantibioticimpactonwithinpatientdynamicsofextendedspectrumbetalactamaseresistance |